In addition, inhibition of Shh by the Smo antagonist LDE225 (Sonidegib) in combination with Imatinib, reduced the self-renewal capacity of CD34+ CP-CML and their engraftment in NSG mice, without affecting HSCs [46]. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.